To include your compound in the COVID-19 Resource Center, submit it here.

cAd3-EBO Z: Phase I started

Bavarian Nordic A/S (CSE:BAVA, Kvistgaard, Denmark) said the University of Oxford began an open-label, dose-escalation,

Read the full 169 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE